Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA7 | P43166 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969539 | 0.90 | TSHR (0.33) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15166890 | 0.84 | MAPK1 (0.33) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19748487 | 0.81 | TSHR (0.36) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21289831 | 0.79 | TSHR (0.34) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16486223 | 0.78 | ALDH1A1 (0.36) | TSHRCYP2D6ALDH1A1LMNAKDM4E | |
| SCHEMBL9017781 | 0.77 | TSHR (0.43) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL22747787 | 0.76 | CYP2D6 (0.33) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16700705 | 0.76 | CYP2D6 (0.33) | TSHRCYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16700783 | 0.75 | CYP2D6 (0.35) | TSHRCYP2D6ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL23886668 | 0.75 | NPSR1 (0.35) | ALDH1A1LMNAKDM4EHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | TSHR 733/4885CYP2D6 4626/4885ALDH1A1 1250/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | TSHR 3290/4885CYP2D6 1780/4885ALDH1A1 3620/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | TSHR 2133/4885CYP2D6 2037/4885ALDH1A1 2189/4885 |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | TSHR 3980/4885CYP2D6 4226/4885ALDH1A1 4067/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | TSHR 1890/4885CYP2D6 2773/4885ALDH1A1 3725/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | TSHR 142/4885CYP2D6 249/4885ALDH1A1 1374/4885 |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | TSHR 1890/4885CYP2D6 2773/4885ALDH1A1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.